Zacks: Analysts Expect TCR2 Therapeutics Inc. (NASDAQ:TCRR) Will Announce Earnings of -$0.75 Per Share

Wall Street analysts expect that TCR2 Therapeutics Inc. (NASDAQ:TCRR) will report ($0.75) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for TCR2 Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.86) and the highest estimate coming in at ($0.66). TCR2 Therapeutics posted earnings per share of ($0.55) in the same quarter last year, which indicates a negative year over year growth rate of 36.4%. The company is expected to issue its next quarterly earnings results on Thursday, March 10th.

On average, analysts expect that TCR2 Therapeutics will report full-year earnings of ($2.65) per share for the current year, with EPS estimates ranging from ($2.77) to ($2.56). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.83) per share, with EPS estimates ranging from ($3.33) to ($2.42). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that cover TCR2 Therapeutics.

TCR2 Therapeutics (NASDAQ:TCRR) last announced its quarterly earnings results on Wednesday, November 10th. The company reported ($0.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.06).

Several analysts have recently issued reports on the stock. HC Wainwright reduced their target price on shares of TCR2 Therapeutics from $25.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday. SVB Leerink reduced their target price on shares of TCR2 Therapeutics from $8.00 to $7.00 and set a “market perform” rating for the company in a research note on Wednesday, November 10th. Zacks Investment Research upgraded shares of TCR2 Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Friday. Truist Securities reduced their target price on shares of TCR2 Therapeutics from $40.00 to $29.00 and set a “buy” rating for the company in a research note on Monday, September 20th. Finally, BMO Capital Markets reduced their target price on shares of TCR2 Therapeutics from $44.00 to $38.00 and set an “outperform” rating for the company in a research note on Thursday, October 21st. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $24.25.

Shares of NASDAQ TCRR traded up $0.10 during trading on Friday, hitting $4.01. The stock had a trading volume of 590,352 shares, compared to its average volume of 688,685. TCR2 Therapeutics has a 12 month low of $3.81 and a 12 month high of $34.45. The firm has a fifty day moving average of $5.25 and a two-hundred day moving average of $9.98.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TCRR. Alliancebernstein L.P. lifted its holdings in TCR2 Therapeutics by 31.9% during the second quarter. Alliancebernstein L.P. now owns 27,300 shares of the company’s stock valued at $448,000 after purchasing an additional 6,600 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in TCR2 Therapeutics by 20.6% during the second quarter. New York State Common Retirement Fund now owns 27,727 shares of the company’s stock valued at $455,000 after purchasing an additional 4,734 shares during the last quarter. Swiss National Bank lifted its holdings in TCR2 Therapeutics by 4.0% during the second quarter. Swiss National Bank now owns 54,500 shares of the company’s stock valued at $894,000 after purchasing an additional 2,100 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in TCR2 Therapeutics by 22.2% during the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 15,521 shares of the company’s stock valued at $255,000 after purchasing an additional 2,822 shares during the last quarter. Finally, Sei Investments Co. lifted its holdings in TCR2 Therapeutics by 24.4% during the second quarter. Sei Investments Co. now owns 192,755 shares of the company’s stock valued at $3,163,000 after purchasing an additional 37,814 shares during the last quarter. 78.84% of the stock is currently owned by institutional investors and hedge funds.

TCR2 Therapeutics Company Profile

TCR2 Therapeutics, Inc is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It also involves in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development.

See Also: Analyzing a company’s cash flow statement

Get a free copy of the Zacks research report on TCR2 Therapeutics (TCRR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TCR2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.